相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- An 83-year-old patient with stage IV esophageal cancer has survived over four years on a clinical trial combining tucatinib with standard chemotherapy and Herceptin at the University of Colorado Cancer Center. - The treatment regimen caused the patient's metastatic disease to disappear after just a few treatments, leaving only the primary esophageal tumor which has remained stable. - This represents a significant improvement over the average 1.5-year survival for metastatic esophageal cancer patients receiving standard care at the time. - The patient has maintained excellent quality of life, receiving 115 infusions over four years while continuing annual vacations and normal activities.
- Researchers at the University of Colorado Cancer Center have launched the first clinical trial combining PARP inhibitors with SM08502 (Cirtuvivint), targeting resistant ovarian cancer through dual mechanisms. - The combination therapy addresses PARP inhibitor resistance by targeting WNT signaling, a backup survival system activated when cancer cells become resistant to PARP drugs. - Laboratory studies demonstrated that SM08502 alone slowed tumor growth, while the combination enhanced cancer cell death, increased DNA damage, and reduced immune suppression. - This bench-to-bedside innovation represents a novel oral treatment approach that may extend beyond ovarian cancer to other tumors with similar resistance mechanisms.
- The phase 3 KEYNOTE-630 trial found that adjuvant pembrolizumab did not significantly improve progression-free survival in patients with high-risk cutaneous squamous cell carcinoma following surgery and radiation. - Despite missing its primary endpoint, pembrolizumab demonstrated a 50% reduction in cancer recurrence rates, with locoregional recurrence occurring in 13.8% versus 25.3% of placebo patients. - The competing phase 3 C-POST trial showed cemiplimab reduced the risk of recurrence or death by 68% compared to placebo, with FDA approval expected for this indication. - Treatment paradigms are shifting toward neoadjuvant immunotherapy approaches, with upcoming trials exploring response-adapted surgery and radiation strategies.
- Real-world data from 877 patients and clinical trial data from 702 patients demonstrate that most cytokine release syndrome and neurological events with lisocabtagene maraleucel occur within 15 days of infusion and are not severe. - Among patients experiencing late-onset adverse events after day 15, the vast majority were grade 1/2 events that resolved without requiring intensive care unit-level management. - The findings support optimized monitoring strategies that could improve patient access to CAR-T therapy while maintaining safety standards across multiple blood cancer indications.
- Researchers analyzed 678 AML patients and found that both gene mutations and leukemia cell maturity affect response to venetoclax plus hypomethylating agents treatment. - Patients with monocytic AML lacking the NPM1 mutation were nearly twice as likely to die from the disease compared to other patient groups. - The findings offer doctors a new risk classification system to better predict treatment response and guide personalized therapy decisions for AML patients. - This research represents a major step toward personalized medicine in AML by combining genetic and cellular factors to optimize treatment selection.
- Flatiron Health and University of Colorado Cancer Center launch collaboration to implement Clinical Pipe™, an advanced EHR-to-EDC connector that streamlines clinical trial data capture. - The technology demonstrates remarkable efficiency, enabling transfer of over 11,000 data points with average submission times of just 37 seconds, significantly reducing administrative burden. - This partnership aims to expand clinical trial access and accelerate cancer research by automating data entry processes across UCHealth's network of care facilities.
- Extended follow-up data from the phase 3 CROWN trial demonstrates superior efficacy of lorlatinib over crizotinib, with median progression-free survival not yet reached at 60.2 months. - Strategic dosing approach starting at 50mg and gradually increasing to manage neurocognitive side effects is recommended, differing from the standard 100mg daily dosing in prescribing information. - Approximately 60% of patients may experience neurocognitive adverse events, requiring careful monitoring and proactive management through dose optimization.
- A phase one trial of botensilimab and balstilimab shows promising results in treating sarcomas, particularly angiosarcoma, which typically responds poorly to immunotherapy. - The combination therapy yielded a 23% response rate across all sarcoma patients, with an impressive 44% response rate specifically in angiosarcoma cases. - Botensilimab blocks CTLA4, enhancing T cell education, while balstilimab inhibits the PD-1 receptor, preventing tumor cells from suppressing immune attacks. - Further trials are planned to assess the combination's efficacy in newly diagnosed sarcomas, both alone and in conjunction with chemotherapy, to address the unmet need for approved checkpoint inhibitors.
- A recent clinical trial evaluated the addition of pembrolizumab to lenvatinib for patients with progressive thyroid cancer resistant to radioactive iodine. - The combination therapy demonstrated an improved duration without relapse compared to the standard-of-care treatment with lenvatinib alone. - The study, published in Clinical Cancer Research, suggests a potential new treatment approach for this challenging patient population. - Led by Dr. Bryan Haugen, the multi-center trial offers hope for patients with limited options.
